SHL sinks $40M into Taiwanese device production

SHL will hire several hundred new employees in Taiwan this year and pour $40 million into expanding its production there of drug delivery-related medical devices including auto injectors, pen injectors, infusors and inhaler systems. The company notes that it has already spent $100 million over the previous 5 years with the same goal in mind, boosting capacity at several of its plants in Taiwan and elsewhere in China. What's driving the expansion? SHL cites the rapid growth of the biologic injectable market globally, which means "device suppliers are under pressure to broaden the range of services they can provide." Item

BD&L Summit

Deal-Making Insights for the Life Sciences Industry

Bringing together key deal-makers and serving as an open forum for cross-functional business development and legal teams to share valuable insights and actionable strategies on successfully managing alliances, licensing agreements, and M&A deals.